B Capital, a venture capital firm based in Los Angeles, has set aside $500 million to start a new fund that looks for business prospects in the healthcare industry.

The Healthcare Fund of B Capital According to a release, I began when Dr. Robert Mittendorff joined B Capital as a General Partner in April 2021 to oversee the fund and its larger global healthcare activities.

The healthcare team of the fund is concentrated on investing in companies that are creating ground-breaking products and solutions that will shape the future of healthcare.

According to Howard Morgan, chair and general partner of B Capital, “B Capital has decades of combined operating expertise in the healthcare industry and a deep technical emphasis that allows us to select and assist the top companies in the space.”

B Capital’s strategy for international venture and growth investment, according to Morgan, places founders and management teams front and center and surrounds them with the resources they need to alter sizable markets. This strategy includes its cooperation with Boston Consulting Group (BCG).

B Capital is presently investing in businesses in India, including the B2B vendor digitizing platform for brands and enterprises Bizongo, the online trucking platform BlackBuck, the social commerce startup Meesho, the edtech major Byju’s, and the online pharmacy firm Pharmeasy.

Technology developments in biology, artificial intelligence (AI), and automation are revolutionizing the market, and new business models are enabling the fusion of established firms. B Capital has a rare chance right now to uncover and support businesses that are changing the healthcare industry by utilizing our active investment strategy and dedicated healthcare capital, according to Mittendorff.

The current B Capital global healthcare portfolio consists of approximately 20 firms in the United States, Asia, and Europe, ranging from early-stage startup ventures to late-stage ventures, covering health tech, digital health, biotech, and med tech.

The most recent additions include Hotspot Therapeutics, an AI-enabled drug discovery firm; Triumvira, a revolutionary cell treatment platform in clinical development; CapitalRX, a tech platform for pharmacy benefit administration; and Carlsmed, an AI-enabled, tailored spinal implant business.

B Capital announced the closing of Growth Fund III and linked funds in January of this year, totaling almost $2.1 billion in capital commitments. B Capital now has about $6.3 billion in assets under management following this fund closes.

Raj Ganguly, co-founder and managing partner of B Capital, told ET that the company expects the higher corpus to enable it to maintain its positive outlook on India and Southeast Asia opportunities.

The $250 million life sciences and healthcare fund formed last year by Eight Roads Ventures and HealthQuad are two additional funds with a focus on healthcare and interests in India.